Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles

Wernig, Karin; Griesbacher, Martin; Andreae, Fritz; Hajos, Franz; Wagner, Julian; Mosgoeller, Wilhelm; Zimmer, Andreas

doi:10.1016/j.jconrel.2008.06.005

Cited by 39 publications

(41 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biodegradable polymers have received a lot of attention due to their biocompatibility, possibility for surface modifications and sustained release of the drug [8]. Polymeric particles have also been extensively studied for the delivery of pulmonary medicines; these include asthmatic drugs [9,10], anti-tuberculosis drugs [11] and anti-cancer drugs [12,13]. Many types of liposomal nano-formulations have been investigated for their drug delivery properties as well.…”

Section: Nano-sized Drug Carriersmentioning

confidence: 99%

Medical nanoparticles for next generation drug delivery to the lungs

2014

View full text Add to dashboard Cite

Respiratory diseases are an increasing burden for the ageing population. Although our understanding of these diseases has improved significantly over the past decades, diagnostic and therapeutic options for treating lung diseases, such as chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and lung cancer, remain limited. Multidisciplinary approaches that bridge the gap between medicinal and materials sciences will likely contribute to promising new therapeutic and diagnostic solutions. One such multidisciplinary approach is the use of nanoparticles as carriers for the delivery of drugs. The advantages of using nanoparticles to deliver drugs include: increased drug concentration at the disease site; minimised drug degradation and loss; ease of creating inhalable formulations; and the possibility of specific cell targeting. This article gives a brief overview on the emerging field of nanocarriers as drug delivery vehicles for the treatment of lung diseases. @ERSpublications This article provides an overview on the emerging field of nanocarriers as drug delivery vehicles for lung therapy

show abstract

Section: Nano-sized Drug Carriersmentioning

confidence: 99%

Medical nanoparticles for next generation drug delivery to the lungs

2014

View full text Add to dashboard Cite

show abstract

“…26,29,38,39,[54][55][56][57]59,61,69,70,74,75,[79][80][81][82][83][84][85][86][87][88][89][90][91][92][93] Due to their biocompatibility, surface modification capability, and sustained-release properties, polymeric nanoparticles are intensively studied using various important pulmonary drugs. These pulmonary drug include antiasthmatic drugs, 22,26 antituberculosis drugs, 38,39 pulmonary hypertension drugs, 29 and anticancer drugs. 54 However, to avoid accumulation of polymer carriers following repeated dosing, the biodegradability and toxicity of polymers over the long term should be closely examined in the formulation of polymeric nanoparticles for pulmonary delivery.…”

Section: Drugs For Inhalationmentioning

confidence: 99%

Nanomedicine in pulmonary delivery

Mansour¹,

Rhee²,

Wu³

2009

IJN

409

269

View full text Add to dashboard Cite

“…Reproducibility of proticle formation was guaranteed by accurate mixing of equal volumes of the components with a pipette and vortexing for 5 seconds as described previously. 15,17 Batch sizes were used in the range of 500-1000 µL proticle suspensions. The preassembled proticles were incubated with 150 ng/10 µg oligonucleotides of native or fluorescence-labeled gAd for 1 hour at room temperature in an orbital shaker (300 rpm), and were immediately used for the subsequent staining experiments.…”

Section: Preparation Of Gad-coated Proticlesmentioning

confidence: 99%

“…Proticles are biodegradable nanoparticles, which have been previously developed and characterized by our group for the delivery of various active compounds, including antisense oligonucleotides or small peptides. [14][15][16][17] Proticles can be formulated by directed self-assembly of anionic and cationic biopolymers in combination with protamine, a cationic 32 amino acid peptide used in depot insulin. These nanoparticles can be coated with drug targeting sequences in a second production step.…”

Section: Introductionmentioning

confidence: 99%

Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques

Almer

Wernig²,

Saba-Lepek³

et al. 2011

IJN

Self Cite

View full text Add to dashboard Cite

Background: Atherosclerosis is a leading cause of mortality in the Western world, and plaque diagnosis is still a challenge in cardiovascular medicine. The main focus of this study was to make atherosclerotic plaques visible using targeted nanoparticles for improved imaging. Today various biomarkers are known to be involved in the pathophysiologic scenario of atherosclerotic plaques. One promising new candidate is the globular domain of the adipocytokine adiponectin (gAd), which was used as a targeting sequence in this study. Methods: gAd was coupled to two different types of nanoparticles, namely protamine-oligonucleotide nanoparticles, known as proticles, and sterically stabilized liposomes. Both gAd-targeted nanoparticles were investigated for their potency to characterize critical scenarios within early and advanced atherosclerotic plaque lesions using an atherosclerotic mouse model. Aortic tissue from wild type and apolipoprotein E-deficient mice, both fed a high-fat diet, were stained with either fluorescent-labeled gAd or gAd-coupled nanoparticles. Ex vivo imaging was performed using confocal laser scanning microscopy. Results: gAd-targeted sterically stabilized liposomes generated a strong signal by accumulating at the surface of atherosclerotic plaques, while gAd-targeted proticles became internalized and showed more spotted plaque staining. Conclusion: Our results offer a promising perspective for enhanced in vivo imaging using gAd-targeted nanoparticles. By means of nanoparticles, a higher payload of signal emitting molecules could be transported to atherosclerotic plaques. Additionally, the opportunity is opened up to visualize different regions in the plaque scenario, depending on the nature of the nanoparticle used.

show abstract

Depot formulation of vasoactive intestinal peptide by protamine-based biodegradable nanoparticles

Cited by 39 publications

References 22 publications

Medical nanoparticles for next generation drug delivery to the lungs

Medical nanoparticles for next generation drug delivery to the lungs

Nanomedicine in pulmonary delivery

Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques

Contact Info

Product

Resources

About